Cancer surgery specialist Lightpoint Medical has been awarded for the Medtech Insight Award for Best Technological Innovation in the Devices and Diagnostics category.
Francesca Oldfield
The company, which is part of the ABHI’s US Accelerator programme, fought off global competition to claim the accolade. The award recognises innovative medical devices and diagnostics making meaningful contributions to advancing patient treatment.
Founded in 2012, Lightpoint Medical is a medical device company that develops molecular imaging and sensing technologies, helping surgeons to detect cancer in real time during surgery. The company’s Sensei technology, a miniaturised intra-operative cancer detection probe, is designed for use in robotic surgery, providing surgeons with a reliable solution to fully remove cancer in one procedure, whilst retaining healthy tissue.
This year, Cancer Research UK figures suggest there will be over 18 million new cases of cancer worldwide, and the disease will account for around one in six deaths globally. By 2030, the incidence rate is set to soar by more than 60%, with over 24 million new cases each year.
David Tuch, CEO Lightpoint Medical, said: “It is an honour to receive this prestigious award and to have our technology recognised as a leap forward in cancer treatment to improve patient outcomes. Our miniature probe provides surgeons with the capability to accurately detect cancer whilst reducing complications and healthcare costs. It is a privilege to be presented with this award.”
Lightpoint Medical aims to radically improve the health outcomes for patients undergoing surgery – the primary treatment for most cancer patients. Despite advances in pre-operative imaging to aid diagnosis, surgeons still rely on the naked eye and sense of touch to detect cancer during an operation.
ABHI’s managing director, International, Paul Benton, said: “We are delighted to hear that one of our US Accelerator companies has been recognised for its incredible achievements in diagnostics. Our programme is designed to provide a springboard for UK companies to the US, and it is always a pleasure to hear of their success on both sides of the Atlantic – we’d like to offer them our heartfelt congratulations!”
